leisure time -WSS

leisure time

author：knowledge 2025-09-04 04:30:10 - browse：116

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： ADA: All diabetes patients should be screened for liver condition

focus

WSS

Solve the antibiotic resistance crisis with preventive drugs

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

STAT Summit: How a Chicago ER doctor tackles gun violence

FDA gives detailed accounting of AI

Synthetic human embryos? Researchers say term is overblown

Hospital price transparency does save money, advocate argues

Wikipedia

leisure time

knowledge

Virginia high school admissions case could be legal follow

Hospital price transparency does save money, advocate argues

After affirmative action ruling, medical educators look to 'holistic review'

Supreme Court rules employers must be more accommodating of religious observance

Sports medicine is finally prioritizing gender equality

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Peter Hotez and the public health issue of online harassment

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

BioMarin wins approval for gene therapy to treat hemophilia A

Thousands protest in Iraq for a second day over burning of Quran in Sweden

entertainment

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

FDA warns J&J's Abiomed: We will regulate your software

FDA struggles to regulate food additives, sometimes for decades

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Tuskegee Airman Raymond Cassagnol dies at 102

focus

entertainment

explore

entertainment